The Food and Drug Administration approved the drug, Inlyta, after concluding it helps prevent the cancer from progressing, the agency said today in a statement.
The drug will provide a new treatment option for as many as 13,000 patients diagnosed with advanced kidney cancer in the U.S. each year, said Subramanian Hariharan, the lead of New York-based Pfizer’s global medical team for Inlyta. Sales of the drug may reach $555 million in 2016, according to the average estimate of three analysts compiled by Bloomberg.
“We’re excited for patients,” Hariharan said today in an interview. “Along with Sutent and Torisel, Pfizer now has three drugs that will help physicians and patients with advanced kidney cancer in the United States.”